The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Biogen Pharmachem Industries Ltd share price was down by -3.16% from the previous closing price of ₹0.95. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

At close: April 11 at 4:00:02 PM EDT ...

An 800-head dairy farm in central Pennsylvania is the first in the United States to create a truly circular energy cycle by using recovered biogas to generate the electricity needed to charge the ...

Guggenheim lowered the firm’s price target on Biogen (BIIB) to $165 from $168 and keeps a Buy rating on the shares. The firm, in its preview of Q1 earnings for 36 commercial-stage companies in ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for ...

This data feed is not available at this time.